{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T20:21:24Z","timestamp":1789676484891,"version":"4.0.1"},"reference-count":32,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2016,4,4]],"date-time":"2016-04-04T00:00:00Z","timestamp":1459728000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2016,5]]},"abstract":"<jats:p>Renal failure (RF) is a common and severe complication of symptomatic myeloma, associated with significant morbidity and mortality. Such patients are commonly excluded from clinical trials. Bortezomib\/dexamethasone (VD)\u2010based regimens are the backbone of the treatment of newly diagnosed MM patients who present with severe RF even those requiring dialysis. We analyzed the outcomes of 83 consecutive bortezomib\u2010treated patients with severe RF (eGFR\u2009&lt;\u200930 ml\/min\/1.73 m<jats:sup>2<\/jats:sup>), of which 31 (37%) required dialysis. By IMWG renal response criteria, 54 (65%) patients achieved at least MRrenal, including CRrenal in 35% and PRrenal in 12%. Triplet combinations (i.e., VD plus a third agent) versus VD alone were associated with higher rates of renal responses (72 vs. 50%; <jats:italic>P<\/jats:italic>\u2009=\u20090.06). Fifteen of the 31 (48%) patients became dialysis independent within a median of 217 days (range 11\u2013724). Triplets were associated with a higher probability of dialysis discontinuation (57 vs. 35%). Serum free light chain (sFLC) level \u226511,550 mg\/L was associated with lower rates of major renal response, longer time to major renal response, lower probability, and longer time to dialysis discontinuation. Rapid myeloma response (\u2265PR within the first month) was also associated with higher rates of renal response. Patients who became dialysis\u2010independent had longer survival than those remaining on dialysis. In conclusion, VD\u2010based triplets are associated with a significant probability of renal response and dialysis discontinuation, improving the survival of patients who became dialysis independent. Rapid disease response is important for renal recovery and sFLCs are predictive of the probability and of the time required for renal response. Am. J. Hematol. 91:499\u2013502, 2016. \u00a9 2016 Wiley Periodicals, Inc.<\/jats:p>","DOI":"10.1002\/ajh.24335","type":"journal-article","created":{"date-parts":[[2016,2,19]],"date-time":"2016-02-19T00:18:29Z","timestamp":1455841109000},"page":"499-502","source":"Crossref","is-referenced-by-count":82,"title":["Bortezomib\u2010based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis"],"prefix":"10.1002","volume":"91","author":[{"given":"Meletios A.","family":"Dimopoulos","sequence":"first","affiliation":[{"name":"Department of Clinical Therapeutics National and Kapodistrian University of Athens, School of Medicine Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Roussou","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics National and Kapodistrian University of Athens, School of Medicine Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Gavriatopoulou","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics National and Kapodistrian University of Athens, School of Medicine Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erasmia","family":"Psimenou","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics National and Kapodistrian University of Athens, School of Medicine Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Eleutherakis\u2010Papaiakovou","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics National and Kapodistrian University of Athens, School of Medicine Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalini","family":"Migkou","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics National and Kapodistrian University of Athens, School of Medicine Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charis","family":"Matsouka","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics National and Kapodistrian University of Athens, School of Medicine Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Despoina","family":"Mparmparousi","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics National and Kapodistrian University of Athens, School of Medicine Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitra","family":"Gika","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics National and Kapodistrian University of Athens, School of Medicine Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eftychia","family":"Kafantari","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics National and Kapodistrian University of Athens, School of Medicine Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Ziogas","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics National and Kapodistrian University of Athens, School of Medicine Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Despoina","family":"Fotiou","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics National and Kapodistrian University of Athens, School of Medicine Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Panagiotidis","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics National and Kapodistrian University of Athens, School of Medicine Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Terpos","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics National and Kapodistrian University of Athens, School of Medicine Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efstathios","family":"Kastritis","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics National and Kapodistrian University of Athens, School of Medicine Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,4,4]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.30.8791"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.2086"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfp679"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2012.14"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2013.803068"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.117176"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.182"},{"key":"e_1_2_5_9_1","first-page":"461","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation","volume":"130","author":"Levey AS","year":"1999","journal-title":"Modification of Diet in Renal Disease Study Group. Ann Intern Med"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404284"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-09-046409"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2405087"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11463"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.1238"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2009.n.059"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190801930506"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.04590908"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfr773"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.131"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.29"},{"key":"e_1_2_5_21_1","first-page":"19","article-title":"Incidence and management of renal adverse events in patients with relapsed and\/or refractory multiple myeloma treated with single\u2010agent carfilzomib","volume":"3","author":"Shah JJ.","year":"2013","journal-title":"Oncology (Williston Park)"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-015-0230-x"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-01-548941"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71125-8"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-01-548826"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.115204"},{"key":"e_1_2_5_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2010.01432.x"},{"key":"e_1_2_5_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25139"},{"key":"e_1_2_5_29_1","article-title":"Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open\u2010label phase 3 trial in transplant\u2010ineligible patients with multiple myeloma","author":"Dimopoulos MA","year":"2015","journal-title":"Haematologica"},{"key":"e_1_2_5_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2012.01.001"},{"key":"e_1_2_5_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2010.01500.x"},{"key":"e_1_2_5_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv325"},{"key":"e_1_2_5_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.60"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.24335","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.24335","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T00:23:35Z","timestamp":1695515015000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.24335"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,4]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["10.1002\/ajh.24335"],"URL":"https:\/\/doi.org\/10.1002\/ajh.24335","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,4]]}}}